Literature DB >> 7528848

Vascular effects of pentoxifylline in humans.

J Kamphuis1, P Smits, T Thien.   

Abstract

In this study, we investigated the vasoactive effects of the alkylxanthine pentoxifylline and its interaction with the nucleoside adenosine in the forearm skeletal muscle vascular bed of 18 normotensive healthy volunteers. Pentoxifylline infusion into the brachial artery in dosages of 100, 300, and 1,000 micrograms/100 ml forearm volume (FAV)/min, induced increments of forearm blood flow (FBF) of 41 +/- 6, 125 +/- 22, and 295 +/- 57%, respectively (n = 12). Calculated forearm vascular resistance (FVR) showed a dose-dependent decrease during pentoxifylline infusion. Concomitant administration of caffeine (100 micrograms/100 ml/min), an adenosine antagonist, did not attenuate the vasodilator response to pentoxifylline (n = 6). Intraarterial (i.a.) infusion of adenosine alone (0.75, 1.5, 3.0, and 4.5 micrograms/100 ml/min) induced a dose-dependent forearm vasodilator response. Concomitant infusion of pentoxifylline (100 micrograms/100 ml/min) did not cause a convincing potentiation of the forearm vasodilator effect of adenosine. This study demonstrates that pentoxifylline induces vasodilation in human forearm skeletal muscle vascular bed of healthy young volunteers. This vasodilator response occurred at concentrations that are probably much higher than those achieved with oral treatment with pentoxifylline. Our data further suggest that pentoxifylline-induced vasodilation is not mediated by adenosine receptor stimulation, but may result from inhibition of the enzyme phosphodiesterase (PDE).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7528848     DOI: 10.1097/00005344-199410000-00016

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  8 in total

Review 1.  [Medicinal vasoactive therapy of microcirculation disorders in rheumatoid arthritis].

Authors:  G Riemekasten; H Schulze-Koops
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

Review 2.  [Raynaud phenomenon in dermatology : Part 2: therapy].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-10       Impact factor: 0.751

3.  Relation of Habitual Chocolate Consumption to Arterial Stiffness in a Community-Based Sample: Preliminary Findings.

Authors:  Georgina E Crichton; Merrill F Elias; Ala'a Alkerwi; Saverio Stranges; Walter P Abhayaratna
Journal:  Pulse (Basel)       Date:  2016-05-03

4.  Pentoxifylline reduces chronic post-ischaemia pain by alleviating microvascular dysfunction.

Authors:  J Vaigunda Ragavendran; A Laferrière; M Khorashadi; T J Coderre
Journal:  Eur J Pain       Date:  2013-07-31       Impact factor: 3.931

5.  Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases.

Authors:  Ming Zhang; Yan-Jun Xu; Shushma A Mengi; Amarjit S Arneja; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2004

Review 6.  Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders.

Authors:  J E Frampton; R N Brogden
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

Review 7.  Immunological mechanisms of pentoxifylline in chronic heart failure.

Authors:  Steven M Shaw; Mohammed K H Shah; Simon G Williams; James E Fildes
Journal:  Eur J Heart Fail       Date:  2009-02       Impact factor: 15.534

Review 8.  Antioxidant Therapy in Graves' Orbitopathy.

Authors:  Giulia Lanzolla; Claudio Marcocci; Michele Marinò
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-14       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.